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Abstract
Epidemiological studies indicate that a higher plasma level of uric acid (UA) associates with the reduced risk of Parkinson’s 
disease (PD). To confirm the role of UA as a biomarker for PD, we evaluated changes in the serum UA level in the 6-hydroxy-
dopamine (6-OHDA)-induced hemiparkinsonism in rat. For this purpose, 6-OHDA was administered in the medial forebrain 
bundle by stereotaxic surgery. According to the apomorphine-induced rotational test, the increased intensity of behavioral 
symptoms as a function of time was associated with the further reduction of UA level. On the other hand, the level of UA 
increased in the midbrain of the injured hemisphere. The level of reduction in the serum UA level of rats with severe and 
moderate symptoms was significantly higher than that of rats with mild symptoms. The immunohistofluorescence and bio-
chemical analyses showed that the serum UA level was also correlated with the death of tyrosine hydroxylase (TH)-positive 
neurons in the substantia nigra pars compacta (SNc), reduced level of striatal dopamine, and severity of oxidative stress in 
the midbrain. The rats with mild symptoms also showed a significant decrease in TH-positive neurons and striatal dopa-
mine level. These findings suggest a positive correlation between the level of reduction in the serum urate level and severity 
of 6-OHDA-induced Parkinsonism. In addition, our findings indicated that UA had no marked neuroprotective effects, at 
least at concentrations obtained in this study. On the other hand, UA was introduced as a biomarker for PD, as a significant 
decline was observed in the serum UA level of rats with mild behavioral symptoms but with significant dopaminergic cell 
death in the SNc.
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Introduction
Parkinson’s disease (PD) is a chronic and progressive neu-
rodegenerative disorder, affecting about 6 million people 
worldwide [1]. The prevalence of PD is expected to dou-
ble within the next 20 years, considering the increasing age 
of the population [2]. The most important characteristic 
of this disease is the progressive degeneration of dopa-
minergic (DA) neurons within the substantia nigra pars 
compacta (SNc) of the midbrain. The pathophysiological 
mechanisms of DA degeneration remain unknown, although 
mitochondrial dysfunction and oxidative stress are believed 
to play important roles in the events leading to DA neuronal 
death. Levodopa treatment removes dopamine deficiency 
and effectively improves movement-related symptoms. How-
ever, it cannot halt or retard progressive neurodegeneration, 
and side effects, such as dyskinesia, are developed in the 
long term [3–6].
PD is currently examined via clinical evaluation of 
extrapyramidal signs, such as tremor, rigidity, slowness or 
absence of voluntary movements, postural instability, and 
freezing. These symptoms occur when more than 70% of DA 
neurons are lost [7, 8]. Therefore, early diagnosis of PD may 
help select and initiate the proper treatment to decelerate the 
neurodegenerative process and disease progression.
Identification of biomarkers for PD can be valuable in 
its early detection. The biomarkers also allow for a better 
follow-up of patients and facilitate objective measurements 
in clinical trials [9]. Nonetheless, research on the biomarkers 
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